KRas polyclonal, anti-human, mouse, rat

Protein Family: Enzymes, GTP-binding Proteins

Pathway and Disease: Signal Transduction, Cell Motility, Cell Communication, Immune System, Endocrine System, Nervous and Sensory Systems, Development and Behavior, Cancers

Description:
KRas (K-Ras 2, Ki-Ras, c-K-ras, cKi-ras) binds GDP/GTP and possess intrinsic GTPase activity. Defects in KRas are a cause of acute myelogenous leukemia (AML), a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Defects in KRAS are also a cause of juvenile myelomonocytic leukemia (JMML), Noonan syndrome type 3 (NS3), and cardiofaciocutaneous syndrome (CFC syndrome).

Alternate Names: GTPase Kras, K-Ras2, Ki-Ras, c-K-ras, c-Ki-ras, KRAS2, RASK2

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: P01116

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human KRas.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.